Free Trial

Moderna (MRNA) Stock Forecast & Price Target

Moderna logo
$26.26 -0.46 (-1.72%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$26.30 +0.04 (+0.17%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
4
Hold
15
Buy
4

Based on 23 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Hold." Out of the 23 analysts, 4 have given a sell rating, 15 have given a hold rating, 3 have given a buy rating, and 1 has given a strong buy rating for MRNA.

Consensus Price Target

$53.58
104.03% Upside
According to the 23 analysts' twelve-month price targets for Moderna, the average price target is $53.58. The highest price target for MRNA is $179.00, while the lowest price target for MRNA is $26.00. The average price target represents a forecasted upside of 104.03% from the current price of $26.26.
Get the Latest News and Ratings for MRNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Moderna and its competitors.

Sign Up

MRNA Analyst Ratings Over Time

TypeCurrent Forecast
5/25/24 to 5/25/25
1 Month Ago
4/25/24 to 4/25/25
3 Months Ago
2/25/24 to 2/24/25
1 Year Ago
5/26/23 to 5/25/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
Hold
15 Hold rating(s)
16 Hold rating(s)
15 Hold rating(s)
9 Hold rating(s)
Sell
4 Sell rating(s)
4 Sell rating(s)
4 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$53.58$58.70$60.63$126.46
Forecasted Upside104.03% Upside115.65% Upside78.85% Upside-24.10% Downside
Consensus Rating
Hold
Hold
Hold
Hold

MRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Moderna Stock vs. The Competition

TypeModernaMedical CompaniesS&P 500
Consensus Rating Score
2.04
2.81
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside104.03% Upside5,353.39% Upside16.40% Upside
News Sentiment Rating
Positive News

See Recent MRNA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/22/2025JPMorgan Chase & Co.
2 of 5 stars
Jessica Fye
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetUnderweight ➝ Underweight$33.00 ➝ $26.00+0.93%
5/2/2025UBS Group
3 of 5 stars
Eliana Merle
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$78.00 ➝ $70.00+153.53%
5/2/2025Barclays
3 of 5 stars
G. Wang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00+44.88%
5/2/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Luca Issi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetSector Perform ➝ Sector Perform$32.00 ➝ $28.00+1.67%
5/2/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Cory Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetIn-Line ➝ In-Line$50.00 ➝ $32.00+17.08%
4/17/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform
4/9/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$39.00 ➝ $32.00+29.98%
3/13/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Geoff Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00+14.25%
2/11/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tim Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetUnderperform ➝ Underperform$41.00 ➝ $34.00+6.68%
1/29/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Salveen Richter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$99.00 ➝ $51.00+13.48%
1/16/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$31.00 ➝ $27.00-19.99%
1/16/2025Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
H. Gillis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$33.00 ➝ $42.00+24.46%
12/18/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
11/18/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Y. Liu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/18/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$115.00 ➝ $69.00+76.83%
11/18/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$58.00+57.39%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform$40.00+0.58%
11/8/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$55.00-4.28%
10/15/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$65.00 ➝ $55.00-4.75%
9/13/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$70.00 ➝ $60.00-9.92%
9/13/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
8/7/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold$85.00 ➝ $80.00-2.79%
5/3/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$91.00 ➝ $106.00-15.20%
6/26/202351job
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUpgrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:34 PM ET.


Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, May 21, 2025. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

Moderna
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Moderna, Inc.:

  • Moderna, Inc. has recently seen an increase in institutional investment, with significant stakes being added by firms like Theleme Partners LLP, indicating strong confidence in the company's future.
  • The current stock price is around $27.99, which may present a buying opportunity for investors looking for potential growth as the market stabilizes.
  • Moderna, Inc. has a market capitalization of approximately $10.82 billion, suggesting it is a well-established player in the biotechnology sector.
  • The company reported earnings that exceeded analysts' expectations, which can be a positive indicator of its financial health and operational efficiency.
  • With a significant portion of its stock owned by institutional investors, which is over 75%, this can provide stability and confidence in the stock's performance.

Moderna
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Moderna, Inc. for these reasons:

  • Moderna, Inc. has reported a negative earnings per share (EPS), indicating that the company is currently not profitable, which can be a red flag for potential investors.
  • The stock has experienced significant volatility, with a 1-year high of $170.47 and a low of $23.15, suggesting uncertainty in its market performance.
  • Recent revenue reports showed a decline compared to the previous year, which may indicate challenges in maintaining sales growth.
  • The company has a negative return on equity, which means it is not generating profit from its shareholders' investments, potentially deterring investors.
  • With a high beta of 1.99, the stock is more volatile than the market, which could lead to greater risk for investors looking for stable investments.

MRNA Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $53.58, with a high forecast of $179.00 and a low forecast of $26.00.

23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 4 sell ratings, 15 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.

According to analysts, Moderna's stock has a predicted upside of 104.03% based on their 12-month stock forecasts.

Moderna has been rated by research analysts at Barclays, Citigroup, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, UBS Group, and William Blair in the past 90 days.

Analysts like Moderna less than other "medical" companies. The consensus rating for Moderna is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRNA compares to other companies.


This page (NASDAQ:MRNA) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners